Phase II Study of Paclitaxel Carboplatin and Radiation Therapy for Locally Advanced or Inoperable Non-Small Cell Lung Cancer (NSCLC)
Phase III Trial of Maintenance Daily Oral VP-16 Versus No Further Therapy Following Induction Chemotherapy With VP-16 (V) Plus Ifosfamide (I) Plus Cisplatin (P) (VIP) In Extensive Small Cell Lung Cancer (SCLC)
A Phase III Hoosier Oncology Group Study of Thoracic Radiotherapy (TRT) Plus Cisplatin (P) and Vinblastin (V) With or Without Hydroxyurea (HX) for Locally Unresectable Non-Small Cell Lung Cancer (NSCLC)
Phase III Study of Cisplatin (C) With or Without Gemcitabine (G) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Cisplatin (P) and Vinblastine (V) Followed by Thoracic Radiotherapy With or Without Hydroxyurea (HX) In Previously Untreated Limited Unresectable Non-Small Cell Lung Cancer (NSCLC)
A Phase II Hoosier Oncology Group Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) Plus Concurrent Radiation Therapy (XRT) for Previously Untreated Limited Small Cell Lung Cancer (SCLC)
A Hoosier Oncology Group Phase II Study of Gemcitabine Plus Cisplatin in Non-Small Cell Lung Cancer (NSCLC)
A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients (PTS) with Extensive Small Cell Carcinoma of the LUNG (SCLC)
A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients with Extensive Small Cell Carcinoma of the Lung (SCLC)
A Phase II Study of Daily Oral VP-16 Plus Ifosfamide Plus Cisplatin (poVIP) for Previously Treated Recurrent Small Cell Lung Cancer (SCLC)
A Phase II Hoosier Oncology Group Trial using CODE Chemotherapy in Patients with Unresectable Stage III or IV Non-Small Cell Lung Cancer (NSCLC)
A Phase II Study of Daily Oral VP-16 + Ifosfamide + Cisplatin for Previously Treated Small Cell Lung Cancer (SCLC)
A phase II Study of concurrent pemetrexed and radiation for poor risk stage III non-small cell lung cancer (NSCLC)
The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation
Erlotinib and bevacizumab in chemotherapy naïve performance status 2 patients with advanced non-small-cell lung cancer
Rates and Risk of Pneumonitis in Non-Small Cell Lung Carcinoma (NSCLC) Patients (pts) Treated with Concurrent Chemoradiation
Paclitaxel (P) plus bevacizumab (B) in patients (pts) with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy trial
Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): a phase I-IIa dose-ranging study
Predictors of toxicity to consolidation docetaxel (D) following cisplatin (P) plus etoposide (E) plus concurrent radiation (XRT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) treated on a phase III randomized trial
Prognostic Factors For Survival In Patients With Unresectable Stage III Non-Small Cell Lung Cancer From a Phase III Randomized Trial
An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC)
Multivariate Analysis of Prognostic Variables Associated with Survival from a Phase III Study of Cisplatin (P) plus Etoposide (E) plus Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
A Phase I-IIa Dose Ranging Study of Pemetrexed plus Cetuximab in Patients (pts) with Recurrent Non-Small Cell Lung Cancer (NSCLC)
Gefitinib plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Phase III Study of Cisplatin (P) plus Etoposide (E) with Concurrent Chest Radiation (XRT) followed by Docetaxel (D) vs. Observation in Patients (pts) with Stage III Non-small Cell Lung Cancer (NSCLC): An Interim Toxicity Analysis of Consolidation Therapy
Interim Safety Analysis of Irinotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer
Meta-analysis of randomized trials evaluating Cisplatin or carboplatin-based concomitant chemoradiation versus radiotherapy alone in locally advanced non-small cell lung cancer
A Randomized Phase III Trial Comparing CPT-11 (Irinotecan HCl; Camptosar Injection)/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated, Extensive, Small-Cell Lung Cancer
Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors
Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors
A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART)
LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC
RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC
P1.18-05 ChemoXRT w/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy
Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer
Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN12-179
A randomized double-blind phase II trial of platinum (P) plus etoposide (E) with or without concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC)
A phase I study of Amrubicin (AMR) and Cyclophosphamide in patients with advanced solid organ malignancies
